GMP IPO
📋 Filings Intelligence
About Contact
LIVE — Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement — financial results, order wins, dividends, mergers and more. Updated live.

—
Filed today
—
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings —

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Bliss GVS Pharma Ltd

Bliss GVS Pharma: Independent Directors Recommend on Open Offer Price

REGULATORY ◆ Monitor Closely MEDIUM RISK
📅 Filed on BSE: 22 Jul 2026, 07:09 PM IST  ·  BSE ID: 3ac5fda8-50bf-401f-ac5a-6b45121ef35a
View Original BSE Filing (PDF)
💡
In Simple Terms
The company's independent directors reviewed and provided recommendations on a public offer to buy shares at INR 299 each.
🤖 AI Summary
  • Independent Directors Committee issued recommendations on an open offer by Anupam Rasayan India Limited.
  • The offer is for 26.00% of Bliss GVS Pharma's expanded share capital.
  • The offer price is INR 299.00 per share.
  • Total offer consideration amounts to INR 829,03,27,552.00.
  • Recommendations are made pursuant to Regulation 26(7) of SEBI SAST Regulations.
🔢 Key Numbers — exact figures from BSE filing, not rounded
Offer Size
2,77,26,848 Equity Shares
Percentage of Expanded Voting Share Capital
26.00%
Offer Price per Share
INR 299.00
Total Consideration
INR 829,03,27,552.00
🏢 How This Affects the Company
💰
Financial Impact
The open offer, if successful, will result in a change in the shareholding structure and potentially a change in control for Bliss GVS Pharma.
⚠️
Risk Impact
The open offer introduces uncertainty regarding the future strategic direction and management of the company until its conclusion.
👥 What This Means For Shareholders
✅
Action Required
Shareholders should review the recommendations of the Committee of Independent Directors and the terms of the open offer.
👤
Who Is Affected
All public shareholders of Bliss GVS Pharma Limited are affected by the open offer and the IDC's recommendations.
🔍
Management Signal
The formation and recommendation of the Independent Directors Committee indicates adherence to SEBI regulations concerning substantial acquisitions.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List — track these upcoming events
Shareholder response to the open offer.
Receipt of all applicable statutory approvals.
Finalization and dispatch of the Letter of Offer.
MEDIUM RISK The open offer process involves regulatory compliance and shareholder acceptance, introducing inherent uncertainties.
💡 Investor Takeaway
The Independent Directors Committee has provided recommendations on an open offer where Anupam Rasayan India Limited proposes to acquire 26.00% of shares at INR 299.00 per share, totalling INR 829,03,27,552.00.
❓ Frequently Asked Questions
What is the total consideration for the Bliss GVS Pharma open offer?
The total consideration for the open offer is INR 829,03,27,552.00.
What is the offer price per share for Bliss GVS Pharma?
The offer price is INR 299.00 per equity share.
Who is making the open offer for Bliss GVS Pharma?
The open offer is made by Anupam Rasayan India Limited together with Mates Visa Consultancy Private Limited.
What percentage of Bliss GVS Pharma shares does the open offer cover?
The open offer covers up to 26.00% of the expanded voting share capital.
Which committee provided recommendations on the Bliss GVS Pharma open offer?
The Committee of Independent Directors (IDC) of Bliss GVS Pharma provided the recommendations.

Questions based on this BSE filing only. For information purposes.

⚠️ For Information Only — Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector — takes 5 seconds.